Puma Biotechnology Inc., based in Westwood, has struck an up-to-$35-million deal with Pint Pharma International to commercialize its signature cancer drug in Latin America.
Puma announced this week it had struck a licensing agreement with the Switzerland-based firm to gain entry into the Central and South American markets.
Pint Pharma will seek regulatory approval to sell Puma’s Nerlynx drug for HER2-positive breast cancer from Mexico to Argentina. The drug has yet to be approved outside the U.S.
Puma will receive up to $34.5 million in upfront and milestone payments, plus double-digit royalties on its cancer drug, also known as Neratinib.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China
- Puma Bio Shares Soar After Tripling Q4 Earnings From Cancer Drug Sales
- European Regulators Give an Early Nod to Cancer Treatments From Puma, Kite
- Puma Biotech Loses $300M, Drug Sales Exceed Expectations
- Puma Cancer Drug Sales Rise 41 Percent in Q2
- Puma Biotechnology Added to Nasdaq Biotech Index
- Puma Biotechnology Stock Tumbles After Thumbs Down by Euro Drug Regulators
- Puma Leaps to SE Asia with Licensing Deal